Sbir phase II - monthly status reports
Ended Definitive Contract Awarded Last action
- Contract number
- W911QY16C0051
- Awardee
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $999,928
Award facts
- Contract value 100% obligated
- $999,927.74 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- PSC
- AJ11 General Science And Technology R&D Services; General Science And Technology; Basic Research
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $499,780 | |
| Other Administrative Action | $0 | |
| Original award | $500,148 |
About this award
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the Joint PEO Chemical and Biological Defense, a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California. The $999,927.74 Firm Fixed Price contract is for monthly status reports related to SBIR Phase II research and development efforts. Mapp Biopharmaceutical is a key player in advancing treatments for viral hemorrhagic fevers and other emerging infectious diseases, including Ebola, Sudan, Marburg, and botulinum neurotoxin. The company has received significant federal funding through contracts and grants to support its work on medical countermeasures and has collaborated with various government agencies and research organizations in this domain.
Quick answers
Who was awarded contract W911QY16C0051?
W911QY16C0051 was awarded to Mapp Biopharmaceutical, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on May 27, 2016.
How much is contract W911QY16C0051 worth?
The government has obligated $999,928 on W911QY16C0051.
Which agency awarded contract W911QY16C0051?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY16C0051, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY16C0051 competed?
The extent of competition for W911QY16C0051 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award